Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Characterisation of Immunological and Molecular Changes Evolving in Patients Undergoing Radiotherapy (CHIMERA) (CHIMERA)

9 de noviembre de 2026 actualizado por: Royal Marsden NHS Foundation Trust

Radiotherapy is thought to trigger an immune response, and the particular type of immune response may depend on the biology of individual tumours. By studying changes in the immune response and tumour biology during and after radiotherapy, we will gain a better understanding of how different types of radiotherapy, and different tumour types, affect the immune response. This is important for optimising personalised radiotherapy treatment, including in combination with other immunotherapy agents. There is minimal published data reporting feasibility of the above approach, or to guide power calculations. This means pilot work is needed to establish both feasibility and proof-of principle.

The CHIMERA protocol is a non-interventional single site study involving sample collection (blood and tumour samples) from patients before, during and after radiotherapy. A maximum of four tumour research biopsies are further optional research samples. The primary and secondary objectives of the CHIMERA protocol are to establish feasibility of longitudinal characterisation of firstly the immune response, and secondly tumour biology before, during and after radiotherapy.

Any patient receiving radiotherapy at The Royal Marsden NHS Trust is eligible for CHIMERA provided they are able to provide informed consent, attend follow up appointments and do not have an immunosuppressive infection.

If feasibility criteria are met for profiling of the immune response and tumour, CHIMERA will provide both preliminary data and proof-of-principle for larger studies in single tumour sites. CHIMERA is sponsored by the Institute of Cancer Research, LONDON. Funding is also provided by the Institute of Cancer Research.

Descripción general del estudio

Tipo de estudio

De observación

Inscripción (Estimado)

94

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Anna Dr Wilkins, FRCR, MRCP, MB
  • Número de teléfono: 4020 0208 642 6011
  • Correo electrónico: Anna.Wilkins@icr.ac.uk

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • London, Reino Unido, SW3 6JJ
        • Reclutamiento
        • Royal Marsden NHS Foundation Trust
        • Contacto:
          • Anna Wilkins, FRCR, MRCP, MB
          • Número de teléfono: 4020 0208 642 6011
          • Correo electrónico: Anna.Wilkins@icr.ac.uk

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

N/A

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Patients receiving any type of radiotherapy are eligible for CHIMERA with lung, head and neck, bladder, cervical or rectal cancer

Descripción

Inclusion Criteria:

  • Patients receiving any type of radiotherapy are eligible for CHIMERA provided they are at least 18 years of age and can attend routine follow up appointments

Exclusion Criteria:

  • As immunodeficiency due to HIV/AIDS or other infective or autoimmune immunological conditions may impact feasibility and results of immune profiling, immunosuppressed patients due to infection such as HIV, Hepatitis B/C are excluded.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Lung cancer 1

5 patients with peripheral lung tumours and 5 patients with central lung tumours receiving radical radiotherapy without chemotherapy will be recruited.

Tissue and blood sample collection

Lung cancer 2

12 patients. To establish the feasibility of ctDNA profiling before, during and after radiotherapy for non-small cell lung cancer (NSCLC).

Tissue and blood sample collection

Head and Neck cancer

This pilot includes 12 patients (6 HPV+ and 6 HPV-) head and neck cancer patients

Tissue and blood sample collection

Cervical cancer

12 patients to establish the feasibility of tumour TCR-Seq profiling before, during and after radiotherapy for cervix cancer. This includes patients receiving either radiotherapy or chemoradiotherapy

Tissue and blood sample collection

Bladder cancer 1

12 patients to establish the feasibility of collecting urine-derived lymphocytes suitable for flow cytometry before, during and after chemoradiotherapy.

Tissue and blood sample collection

Bladder cancer 2

24 patients To establish the feasibility of tumour TCR-Seq profiling before, during and after chemoradiotherapy for bladder cancer, in comparison to a cystectomy sample.

Tissue and blood sample collection

Rectal cancer 1

12 patients To determine the feasibility of detecting changes in gene expression using multiple tissue samples during chemoradiotherapy treatment for rectal cancer

Tissue and blood sample collection

Rectal cancer 2

12 patients To determine the feasibility of detecting changes in gene expression using multiple tissue samples during radiotherapy treatment for rectal cancer

Tissue and blood sample collection

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The feasibility of measuring the change in immune cell repertoire before, during and after radiotherapy
Periodo de tiempo: defined as successful profiling of the immune cell repertoire in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.

establishment of proof-of-principle that immune changes occur during and after radiotherapy. Measurement tool is multiparametric flow cytometry immune panel.

defined as successful profiling of the immune cell repertoire in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The feasibility of evaluation of ctDNA dynamics before, during and after radiotherapy
Periodo de tiempo: Feasibility is defined as successfully measurement of ctDNA dynamics in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.

The feasibility of evaluation of ctDNA dynamics before, during and after radiotherapy. Measurement tool is targeted DNA sequencing with reference to baseline tumour.

Feasibility is defined as successfully measurement of ctDNA dynamics in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

20 de mayo de 2022

Finalización primaria (Estimado)

30 de junio de 2028

Finalización del estudio (Estimado)

30 de junio de 2033

Fechas de registro del estudio

Enviado por primera vez

28 de enero de 2022

Primero enviado que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

No plan

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir